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Abstract 
Oncolytic viruses (OV) are genetically modified viruses specifically designed to 
lyse cancerous cells while leaving normal tissue intact. Within the tumor 
microenvironment, the angiogenic and inflammatory responses following OV inoculation 
have significantly limited the efficacy of oncolytic herpes simplex virus (oHSV) in clinical 
trials. Physiological levels of copper support angiogenesis and have been shown to 
inhibit the infection and replication of wild-type HSV. 
Here, we tested if OV replication and cytotoxicity are inhibited by copper and if 
this inhibition can be rescued by ATN-224, a second generation analog of ammonium 
tetrathiomolybdate (TM). TM is a copper-chelating agent that is FDA-approved for the 
treatment of Wilson’s disease and is currently under investigation as an anti-angiogenic 
and anti-neoplastic agent in clinical trials. Under serum concentration of copper, both 
OV replication and glioma cell killing were significantly inhibited (P<0.001). ATN-224 
treatment rescued this copper-mediated inhibition of OV replication and glioma cell 
destruction in vitro (P<0.01). 
The anti-tumor efficacy of this combination therapy was evaluated in vivo using 
two xenograft glioma models. First, mice implanted with subcutaneous U251T3 gliomas 
were treated with PBS, ATN-224, OV, or OV+ATN224 (n=10). Results indicated that 
average tumor size in the OV+ATN224 group was significantly smaller compared to OV 
alone (21.51 vs. 153.93 mm3, P=0.0383). Next, mice implanted with intracranial 
U87ΔEGFR gliomas were treated as previously (n=8). Kaplan-Meier analysis revealed 
increased mean survivals for the OV+ATN224 group compared to OV alone (43.875 vs. 
24.000 days). 
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Testing for a biological explanation for this enhanced efficacy, we treated mice 
daily with ATN-224 or PBS via gavage. OV was administered intravenously, and blood 
was drawn to detect virus presence. Serum derived from ATN-224-treated mice 
revealed increased viral presence in vivo compared to PBS-treated mouse serum. 
Analysis of subcutaneous U251T3 tumors from mice receiving intratumoral OV 
treatment showed that ATN-224-treated tumors had significantly increased viral 
replication in vivo compared to PBS-treated tumors (P<0.05). Similarly, when OV was 
administered intravenously, ATN-224-treated tumors again displayed increased viral 
presence compared to PBS-treated tumors. Therefore, the reduced tumor growth and 
increased survival previously shown in vivo might be associated with enhanced viral 
replication.  
Collectively, our results strongly suggest that the co-treatment of ATN-224 with 
OV can significantly improve the poor efficacy profile of conventional clinical oncolytic 
virotherapy. 
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Chapter 1: Introduction 
Despite decades of research, over 1500 people die from cancer in the United 
States every day1. Over the years, highly-funded research has led to an understanding 
of the pathogenesis of cancer and to both non-specific and targeted therapies for 
treating patients. While these treatments have proved efficacious in some cancer types, 
there remains a dire need for a novel strategy for a large number of cancers. 
Brain Cancer 
 Although primary brain tumors represent a relatively low proportion of all cancers, 
the cancer-related morbidity and mortality emphasizes a significant need for attention to 
discovering effective treatments. Affecting just 48.47 in 1,000,000 children and 24.55 in 
100,000 adults, brain tumors constitute less than 2% of all primary malignant cancers2-3. 
Nonetheless, brain tumors are a very lethal, aggressive disease. 
 The World Health Organization (WHO) classifies primary brain tumors based on 
their morphological and immunohistochemical features and also on their presumed cell 
of origin. The WHO classification organizes gliomas, or tumors arising from the glial 
cells that nourish and protect neurons, into a four-tiered grading scheme that ranges 
from WHO grade I (least malignant) to WHO grade IV (most malignant). Grade I tumors, 
primarily pilocytic astrocytoma, have limited potential for malignant progression and can 
often be cured by surgical resection. Grade II tumors, or diffuse astrocytoma, grow fairly 
slowly with diffuse infiltration into neighboring brain tissue. Anaplastic astrocytoma, a 
WHO grade III lesion, demonstrates rapid growth and tends to infiltrate surrounding 
brain tissue. Glioblastoma multiforme (GBM), or WHO grade IV astrocytoma, is the 
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most aggressive and most prevalent type of glioma and is characterized by very rapid 
proliferation and extensive infiltration into surrounding tissue.4 
 Because some non-classic, high grade gliomas, such as anaplastic astrocytoma 
and GBM, can display little cellular differentiation and can therefore lack visibly distinct 
pathological features, the diagnosis and prognosis of tumors with such non-classical 
histology can be variable and also controversial. A more objective approach to glioma 
classification focuses on analyses of molecular genetics of tumors. For example, one 
variant of glioblastoma, small-cell GBM5, is characterized by a gain in chromosome 7 
(epidermal growth factor receptor, EGFR) and a loss in chromosome 10q (PTEN). Gene 
expression profiles (GEP) have shown a remarkable ability to distinguish histologically 
ambiguous high-grade gliomas (e.g. GBM and anaplastic oligodendrogliomas) in a 
clinically relevant manner6. In 2009, Gravendeel et al. identified six molecular subtypes 
of gliomas, including GBM, with distinct prognoses7. Gene expression profiling provides 
a more accurate prognosis for high-grade gliomas than does the traditional histological 
approach and enables appropriate therapies to be tailored to specific tumor subtypes8. 
The current standard of treatment for GBM is surgical resection, followed by 
radiation and concurrent daily low-dose temozolomide chemotherapy. This conventional 
treatment method offers patients with GBM a median survival of just 14.6 months and a 
dismal 26% two-year survival rate3. A potential treatment modality for cancers of this 
severity lies in oncolytic virus therapy. 
Oncolytic Virus (OV) Therapy 
 Oncolytic viruses (OV) are genetically-modified or naturally-selected strains of 
viruses that are capable of specifically replicating in and lysing cancerous cells while 
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avoiding propagation in normal tissue. This is accomplished through the deletion of viral 
genes that are necessary for its self-propagation. Such an attenuated virus will only be 
able to propagate in an actively dividing cell that will provide these missing gene 
products, i.e. a cancer cell. Furthermore, to increase efficacy, these OVs may use 
tumor-specific promoters to drive propagation-necessary genes that have been 
deleted9. Such a tumor-specific replication of virus will result in lytic destruction of 
infected malignant cells; normal cells in the brain—which are not actively dividing—will 
not allow viral DNA replication and will be protected from lysis. 
 An example of this type of OV is rQnestin34.5. The genome of this oncolytic 
herpes simplex virus type 1 (oHSV) is characterized by two basic alterations that render 
the virus tumor-selective in its replication and propagation. One is the disruption of the 
viral UL39 locus, which codes for the large subunit of ribonucleotide reductase, a 
protein critical for the synthesis of DNA precursors10. The second is the deletion of both 
copies of the viral γ1 34.5 gene, which encodes a neurovirulent protein product 
necessary for viral utilization of host cell translational machinery9. Although these gene 
deletions allow this mutant HSV-1 to be more tumor-selective, they can also attenuate 
the titer of progeny virus in infected cells and thus limit the overall efficacy of OV 
therapy11. 
 To counteract this potential limitation, rQnestin34.5 (isolated from the F strain of 
HSV-1) contains one copy of the γ1 34.5 gene that has been reinserted into the viral 
genome under the control of a tumor-specific promoter. One gene that is specifically up-
regulated in malignant glioma codes for the intermediate filament protein, nestin12. 
While expressed during neuronal embryogenesis and over-expressed in brain cancer, 
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nestin protein expression is shut off in most regions of the adult brain. In the 
rQnestin34.5 virus, a nestin promoter element drives the expression of the γ1 34.5 gene, 
thus enhancing both the neurovirulent potential and the tumor specificity of this OV 
within glioma cells9. (Figure 1A) 
 In this study, a second oHSV was utilized based on experimental conditions 
previously published 13. Similar to rQnestin34.5, the hrR3 virus (isolated from the KOS 
strain of HSV-1) also contains a disrupted UL39 gene locus10. However, hrR3 exhibits 
two functional copies of the γ1 34.5 gene, and so potentially this virus is not as tumor-
selective as is rQnestin34.5. (Figure 1B) 
 Many types of oncolytic viruses, including oHSV, have been tested in clinical 
trials in patients with a diverse range of cancers, including gliomas (Table 1). Having 
been evaluated in phase I, phase II and now phase III clinical trials14, OV therapy has 
not revealed evidence of dose-related toxicities, although trial results have been 
inconclusive with respect to OV effectiveness and patient survival. This observation has 
encouraged the field to research potential limitations to effective OV therapy. 
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Wild type HSV-1 KOS strain
hrR3 has lacZ gene insert to 
disrupt ICP6 locus
Wild type HSV-1 F strain
rQnestin34.5
A.
B.
 
Figure 1. Schematic maps of genomes of rQnestin34.5 and hrR3 oncolytic viruses. A) Genetically 
modified from HSV-1 F strain (wild type), rQnestin34.5 is characterized by deletions in both copies of the 
γ1 34.5 gene and by insertion of green fluorescent protein (GFP) cDNA into the UL39 gene (also known 
as ICP6, coding for ribonucleotide reductase). The rQnestin34.5 construct shows the site of 
recombination of the hybrid promoter (nestin enhancer and hsp68 minimum promoter)-γ1 34.5 expression 
cassette. Overall, rQnestin34.5 contains a disrupted UL39 locus and one copy of γ1 34.5 that is under the 
control of a nestin promoter element9. B) hrR3 is genetically engineered from HSV-1 KOS strain (wild 
type). Here, a lacZ gene has been inserted into the UL39 locus, effectively disrupting the gene encoding 
viral ribonucleotide reductase. hrR3 contains both functional copies of the γ1 34.5 gene10. 
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Recruiting patientsNCT00931931
Phase I, 
safety/dose 
toxicity
Non-CNS solid 
tumors
Herpes simplex 
virusHSV1716
Recruiting patientsNCT00554372Phase II, safety/efficacy
Hepatocellular
carcinomaVaccina virusJX-594
Recruiting patientsNCT00769704Phase III, safety/efficacyMelanoma
Herpes simplex 
virus
OncoVEX(GM-
CSF)
Not yet recruitingNCT01174537Phase I/II, efficacy
Glioblastoma
multiforme, 
sarcoma, 
neuroblastoma
Newcastle disease 
virusNDV-HUJ
CompletedNCT00028158Phase Ib/II, safety/efficacy
Recurrent malignant 
glioma
Herpes simplex 
virusG207
CompletedNCT00528684Phase I/II, safety/efficacyMalignant gliomaReovirusREOLYSIN
Recruiting patientsNCT00408590
Phase I, 
safety/dose 
toxicity
Ovarian cancer, 
peritoneal 
cavity cancer
Measles virusMV-CEA
Recruiting patientsNCT00794131
Phase I, 
safety/dose 
toxicity
Advanced solid 
tumorsVaccina virusGL-ONC1
Trial StatusNCT IdentifierTrial DescriptionConditionVirus TypeVirus name
 
Table 1. Oncolytic viruses (OV) in clinical trials. Listed is a sampling of various types of oncolytic 
viruses that are currently being tested for safety and efficacy in clinical trials against a diverse range of 
cancers14. To date, oncolytic viruses have not shown significant effectiveness with respect to patient 
survival in many cancer types. 
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Angiogenesis and the Inflammatory Response 
 The tumor microenvironment is a key factor to consider when studying the 
growth and spread of solid tumors15. Encompassing the extracellular matrix, blood 
vessels, immune cells and mediators of angiogenic and inflammatory responses, the 
tumor microenvironment is embedded in a complex interplay with cancer cells 
themselves. This introduction will focus on tumor angiogenesis and the inflammatory 
response in the context of oncolytic virus therapy. 
An essential component of tumor survival and progression is angiogenesis, or 
the generation of new vasculature within the tumor microenvironment. In fact, in the 
absence of new blood vessel formation, oxygen and nutrients will only be available via 
diffusion, and tumors will be constrained in size to 2 mm in diameter16. Malignant 
gliomas are characterized by the initiation of blood vessel formation. The pathogenesis 
of angiogenesis involves dysregulation of the normal homeostasis of angiogenic and 
anti-angiogenic factors16-19. The resulting vasculature features tortuous vessels, 
exhibiting disruptions in their structural integrity, increased leakiness, uneven focal 
thickness and arteriovenous shunts not seen in normal brain vasculature20. The 
abnormal circulation that results because of this dysregulated vasculature causes 
increased interstitial fluid pressure and reduced tumor oxygenation, which together pose 
a substantial barrier to radiation and chemotherapy21. Tumor angiogenesis is closely 
related to the tumoral inflammatory response, which has significant relevance in the 
context of oncolytic virus treatment. 
A previous study showed that OV treatment both exacerbated the permeability of 
the tumor vasculature and increased the infiltration of immune cells into the tumor 
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microenvironment20. The increased inflammation post-OV treatment ultimately resulted 
in rapid clearance of oncolytic virus, thus hindering the efficacy of OV therapy. 
Interpreting results that show an increased presence of OV in tumors in 
immunocompromised mice compared to in tumors in immunocompetent mice, it has 
been suggested that the robust immune response following OV inoculation is, in part, 
responsible for limiting viral oncolysis22. Additional evidence supporting the idea that 
angiogenesis and inflammation are closely linked in limiting the efficacy of OV therapy 
can be found in the results of the study by Kurozumi et al. They showed that treating a 
tumor with an anti-angiogenic agent, cRGD peptide, normalized vascular permeability 
and reduced OV-induced inflammation, which led to higher viral titers and increased 
mouse survival20. This information suggests that the therapeutic strategy of OV therapy 
should additionally aim at treating tumor angiogenesis, inflammation, or both. 
Importance of Copper 
 Copper is necessary for normal growth and development, as evidenced by two 
prominent syndromes, Menkes disease and Wilson’s disease, that result when copper 
is present in deficiency or in excess, respectively. Menkes disease is a deficiency of 
copper arising from a mutation in a copper-transporting ATPase, which leads to stunted 
growth, neurological abnormalities and kinky hair23. Wilson’s disease is an inherited 
disorder that causes excess accumulation of copper in tissues, resulting in hepatobiliary 
toxicity, neurological abnormalities and psychiatric manifestations24. Copper is relevant 
to oncolytic virus therapy through its roles in angiogenesis and the inflammatory 
response. 
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A key component of blood vessel formation is copper. Copper has been shown to 
be critical for angiogenesis, as it increases the proliferation and migration of endothelial 
cells25. Copper is an essential co-factor for the secretion of several angiogenic factors. 
In breast cancer cell lines, treatment with a copper chelator permitted lower levels of 
pro-angiogenic and pro-inflammatory mediators vascular endothelial growth factor 
(VEGF), fibroblast growth factor (FGF), interleukin (IL)-1a, IL-6 and IL-8 to be released. 
Additionally, rat aortic rings incubated with media from the treated breast cancer cell 
lines displayed reduced vessel outgrowth compared to aortic rings exposed to media 
from untreated cells26. Copper has also displayed synergistic effects with angiogenin, an 
inducer of angiogenesis that is secreted by endothelial cells as well as by tumor cells27. 
Evidence has also pointed to a high copper uptake by cancer cells28, encouraging 
copper chelation as an anti-cancer therapeutic strategy. 
  In addition to its role in angiogenesis, copper may have vital functions in the 
inflammatory and immune processes of the body. Copper is known to have important 
functions in the development and maintenance of the immune system29, as it is 
essential for T-cell proliferation induced by macrophages or by macrophage-mediated 
cytokines. The stress-induced release pathways of FGF-1 and IL-1a are sensitive to 
copper-chelating treatment30, and levels of IL-1b and tumor necrosis factor (TNF)-α 
(important inflammatory cytokines) are significantly correlated with serum copper 
concentrations31. 
 Interestingly, a unique connection exists between copper and HSV-1. Replication 
of wild type HSV-1 is known to be inhibited by copper via copper (II)-mediated DNA 
damage. It is proposed that this damage occurs when Cu(II) ions bind directly to DNA, 
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especially guanosine residues, and result in breakage of the DNA strand32. Due to 
copper’s activity in angiogenesis, the inflammatory process and wild type HSV-1 
inhibition, it may be wise to consider copper in the therapeutic strategy for oncolytic 
virus treatment of cancer. 
Tetrathiomolybdtate (TM) and ATN-224 
 Tetrathiomolybdate (TM) is an oral copper-chelating agent that is currently FDA-
approved for the treatment of Wilson’s disease, showing minimal toxicity in a clinical 
setting33. TM functions by creating a complex with copper and serum albumin, 
effectively restricting cellular uptake of copper. TM has been shown to be effective for 
reducing serum copper levels and inhibiting angiogenesis in a variety of studies. For 
instance, in a murine breast carcinoma model, treatment with TM effectively reduced 
serum copper levels to 20% of baseline, decreased tumor vascularity and resulted in a 
69% reduction in tumor size26. Additionally, in a mouse model of multiple sclerosis, TM 
exhibited strong suppression of inflammatory and immune-related cytokine increases34. 
Inhibition of angiogenesis and tumor metastasis by TM was shown to occur through the 
suppression of the NFκB signaling cascade, which regulates genes important for 
angiogenesis, inflammation, invasion and metastasis35. TM has also shown synergistic 
effects with other cancer treatment modalities, including chemotherapy (doxorubicin) 
and radiation36. 
 ATN-224 is a bis-choline salt that is a second generation analog of 
tetrathiomolybdate (Figure 2). Compared with TM, ATN-224 has superior stability and a 
faster onset of action37-38. It has been proposed that ATN-224 primarily functions by 
inhibiting the activity of Cu/Zn superoxide dismutase-1 (SOD1) in blood cells37, 39 and in 
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endothelial cells37. ATN-224 has completed phase I studies in solid tumors37 and in 
hematological malignancies and is currently under investigation in several phase II trials 
as an anti-angiogenic and anti-neoplastic agent in a variety of cancers14 (Table 2). 
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Figure 2. Structures of TM (ammonium tetrathiomolybdate) and ATN-224 (choline 
tetrathiomolybdate)38. ATN-224 is known to have greater stability and a faster onset of action than TM33, 
34. 
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Drug Condition Trial Description NCT Identifier Trial Status
TM Breast cancer Phase II, safety/efficacy NCT00195091 Recruiting patients
TM Lung cancer
Phase I, 
safety/dose 
toxicity
NCT00560495 Completed
TM Psoriasis vulgaris Phase II, safety/efficacy NCT00113542 Completed
TM Esophageal carcinoma
Phase II, 
safety/efficacy NCT00176800
Active, not 
recruiting
ATN-224 Melanoma Phase II, safety/efficacy NCT00383851 Unknown
ATN-224 Prostate cancer Phase II, safety/efficacy NCT00405574 Unknown
 
Table 2. Clinical trials of TM and ATN-224. TM and ATN-224 are being tested as anti-angiogenic and 
anti-neoplastic agents in several studies against multiple diseases, including various types of cancer14. 
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Objectives of Study 
 To date, oncolytic viruses have been tested in vitro, in animal models and in 
several clinical trials.  While results in vitro and in animal models have shown great 
efficacy, results from clinical trials have been inconclusive with respect to OV 
effectiveness and patient survival. Within the tumor microenvironment, the angiogenic 
and inflammatory responses that follow OV inoculation have been demonstrated to 
significantly limit OV efficacy. Kurozumi et al. showed that treating a tumor with an anti-
angiogenic agent (cRGD peptide) normalized vascular permeability, which suggests the 
potential for greater viral replication. This study also showed in a rat glioma model that 
pre-treatment with cRGD and subsequent OV infection significantly increased survival 
versus treatment with OV alone20. By combining ATN-224 treatment with OV therapy, 
we hope to inhibit angiogenesis (and subsequently inhibit tumoral inflammation) and to 
increase viral replication in order to enhance the efficacy of OV therapy to ultimately 
improve survival of patients with glioblastoma. 
 Specifically, we hypothesize that ATN-224 will improve the efficacy of oncolytic 
virus therapy against malignant glioma by reducing angiogenesis and inflammation in 
the tumor microenvironment, thus enhancing the ability of OV to replicate and lyse 
glioma cells (Figure 3). 
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Figure 3. Proposed mechanism of ATN-224 action. We propose that ATN-224 will inhibit glioma 
growth and metastasis through its anti-angiogenic properties, and we expect the OV to directly kill cancer 
cells as well. In order to prevent copper-mediated DNA damage to OV, we propose that ATN-224 will 
chelate copper (II) ions to negate this effect. Finally, we hypothesize that ATN-224 will also inhibit 
clearance of virus by innate immunity, thus enhancing the overall anti-tumor efficacy of OV therapy. 
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Chapter 2: Materials and Methods 
Chemicals 
 Cupric chloride (CuCl2•H20), ascorbic acid and Crystal Violet powder were 
purchased from Sigma Chemical Co. (St. Louis, MO). Tetrathiomolybdate (TM) analog, 
ATN-224, was kindly provided by Theodoros Teknos, MD (The Ohio State University, 
Columbus, OH). ATN-224 stock solution was created in phosphate buffered solution 
(PBS) at a concentration of 10 mM and was subsequently sterilized by passage through 
0.22 um pore size membrane filters (Millex GP; Millipore, Billerica, MA). Fresh ATN-224 
stock solution was made for each experiment that utilized the drug. Cupric chloride was 
dissolved in distilled water (dH2O) to a concentration of 7 g/L and passed through a 0.22 
um filter. Ascorbate buffer was created by dissolving ascorbic acid in HBSS at a 
concentration of 300 mg/L. For in vitro experiments, ascorbate buffer was used as a 
reducing agent to create more copper (II) ions in order to facilitate viral DNA damage. 
Serial dilutions (1:10) were prepared in ascorbate buffer to make the final Cu(II) 
concentration 7 mg/L. Cells in control group were treated with ascorbate buffer. 
Viruses and Cell Lines 
 rQnestin34.5 is a second-generation oncolytic virus derived from herpes simplex 
virus type 1 (HSV-1) F strain, whose construction and generation has been previously 
described9. It is characterized by insertion of the green fluorescent protein (GFP) gene 
into the HSV-1 UL39 locus, which inactivates the viral ICP6 gene coding for the large 
subunit of ribonucleotide reductase. rQnestin34.5 also carries deletions in both copies 
of the -34.5 gene, whose protein product is necessary for preventing the shutdown of 
eukaryotic protein translation by the host cell. rQnestin34.5 has one copy of the -34.5 
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gene reinserted under a tumor-specific synthetic nestin promoter. hrR3 is another 
genetically engineered HSV-1 mutant, derived from HSV-1 KOS strain, with a disruption 
of the UL39 locus by insertion of the Escherichia coli lacZ gene under control of the 
ICP6 promoter13. Viral stocks were generated in Vero African green monkey kidney 
cells (American Type Culture Collection, Manassas, VA) as previously described40. 
Human U87EGFR glioma cells from our laboratory were stably transfected with a 
plasmid that expresses a constitutively active mutant form of epidermal growth factor 
receptor (EGFR), were maintained in DMEM supplemented with 10% fetal bovine 
serum, 2 mM glutamine, 100-U/mL penicillin, 100-μg/mL streptomycin, and 200-μg/mL 
G418. Human Gli36EGFR gliomas from our laboratory were also stably transfected 
with an EGFR plasmid and maintained in DMEM supplemented with 10% fetal bovine 
serum, 2 mM glutamine, 100-U/mL penicillin, 100-μg/mL streptomycin, 2-μg/mL 
puromycin and 4-μg/mL blasticidin. Human U251T3 gliomas and patient-derived X12V2 
gliomas were cultured in DMEM supplemented with fetal bovine serum (10% for 
U251T3, 2% for X12V2), 2 mM glutamine, 100-U/mL penicillin, and 100-μg/mL 
streptomycin. All cell lines were maintained at 37 °C in a humidified atmosphere at 5% 
CO2. 
In vitro viral replication assay 
 The day before infection, 4.5x105 gliomas were seeded in DMEM 2% FBS in a 6-
cm plate. The day of infection, gliomas were infected with oncolytic virus (OV) at a 
multiplicity of infection (MOI) of 0.1. Prior to infection, ATN-224 was incubated with 
copper for 1 hour at RT, and then OV was incubated with ascorbate buffer ± copper (1 
mg/L) ± ATN-224 (32 uM) for 30 min at RT. Gliomas were infected with OV and 
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incubated at 37°C for 30 min, then cells were washed with PBS for removal of 
unattached virus. At 48 hours post virus infection, cells and media were collected and 
freeze-thawed three times to release the viruses. The number of infectious particles 
(viral titer) present in the resulting supernatants was then determined by performing a 
standard plaque forming unit assay on Vero cells, as previously described41. 
In vitro cytotoxicity assay 
 The day before infection, 5000 glioma cells/well were seeded in DMEM 2% FBS 
in a 96-well plate. The day of infection, gliomas were infected with oncolytic virus (OV) 
at a multiplicity of infection (MOI) of 0.1. Prior to infection, ATN-224 was incubated with 
copper for 1 hour at RT, and then OV was incubated with ascorbate buffer ± copper (1 
mg/L) ± ATN-224 (32 uM) for 30 min at RT. Gliomas were infected with OV, and cell 
survival was measured via crystal violet staining 48 hours post infection. Cells were 
fixed with 1% glutaraldehyde for 15 min at RT then stained with 100 L/well of 0.5% 
Crystal Violet (5 g Crystal Violet powder + 50 mL 95% EtOH + ddH2O = total 1000 mL 
solution) for 15 min while shaking.  Cells were gently washed in water and allowed to 
dry. Crystals were dissolved in 100 L/well of Sorenson’s buffer (3.68 g sodium citrate 
and 12.5 mL of 0.025 M citric acid in 487.5 mL of 50% EtOH). Absorbance was 
measured in a plate reader at 590 nm. 
Animal Studies 
 All mice experiments have been approved by the Institutional Review Board, and 
all mice were housed and handled in accordance with the guidelines of the 
Subcommittee on Research Animal Care of The Ohio State University. Female athymic 
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nude (nu/nu) mice were purchased (Charles River Laboratories, Frederick, MD) at 6-8 
weeks old for all in vivo experiments. 
For subcutaneous tumor studies, U251T3 human gliomas (1.5x107 cells) were 
implanted subcutaneously into the rear flank of nude mice. When tumors reached an 
average size of 100 mm3, tumor-implanted mice were randomly assigned and treated 
daily with ATN-224 (0.7 mg/mouse dissolved in 100 uL PBS) or PBS (100 uL) by 
gavage technique (n=10). Gavage is a method of force-feeding that involves plunging 
liquid down the mouse’s esophagus, so as to ensure equivalent uptake of the drug by 
all mice. At day 13 from the initial ATN-224 treatment, rQnestin34.5 (5x105 pfu) or PBS 
was then administered by a single intratumoral injection. Tumor size was measured 
every day, and tumor volume was calculated using the following formula: volume = 
0.5LW2. 
For intracranial tumor studies, anesthetized nude mice were fixed in a 
stereotactic apparatus, and a burr hole was drilled at 2 mm lateral to the bregma, to a 
depth of 3 mm. U87ΔEGFR human gliomas (1x105 cells in 4 μl Hank's buffered salt 
solution [HBSS]) were implanted. On day 3 after tumor implantation, mice were 
randomly assigned and treated by daily gavage with ATN-224 (0.7 mg/mouse dissolved 
in 100 uL PBS) or PBS (100 uL). On day 10 after tumor implantation, mice were 
anesthetized again and stereotactically inoculated with a single intratumoral injection of 
rQnestin34.5 (5x104 pfu in 4 uL HBSS) or an equivalent volume (4 uL) of PBS at the 
same location as the tumor implantation. Animals were observed daily and were 
euthanized at the indicated time points or when they showed signs of morbidity, i.e. 
when mice become moribund, lethargic, anorexic, dehydrated or distressed. 
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Histology and Immunohistochemistry 
 Tumors were fixed in 4% buffered paraformaldehyde followed by 30% sucrose at 
4°C, then embedded in OCT compound (Tissue Tek, Sakura Finetec, Torrance, CA) 
and cut into 10-μm thick sections. Representative sections were stained with 
hematoxylin & eosin (H&E) and examined by light microscopy. To observe microvessel 
density (MVD), cryosections were treated with purified mouse anti-CD31 (Pharmingen, 
San Jose, CA) as a primary antibody to visualize endothelial cells lining the blood 
vessels (n=3 mice/group), were treated with biotin-SP-conjugated goat anti-rat IgG 
(Jackson ImmunoResearch Laboratories, Inc., West Grove, PA) as a secondary 
antibody, and then were incubated with Vectastain ABC reagent (Vectastain ABC kit, 
Vector Labs, Burlingame, CA) for 30 min at RT. Diaminobenzidine/hydrogen peroxidase 
(Thermo Scientific, Rockford, IL) was used as the chromogen substrate. All slides were 
counterstained with Meyer’s hematoxylin. The three most vascularized areas within the 
tumor (“hot spots") were chosen at low magnification, and vessels were counted in a 
representative high magnification (10x) field in each view field42. Single immunoreactive 
endothelial cells or endothelial cell clusters separate from other microvessels were 
counted as individual microvessels. Mean MVD was calculated as the average number 
of counts per view field. Vessels at the periphery of the tumor were disregarded in the 
MVD counts. The MVD for each therapy group was then averaged together [n=18 view 
fields/group (3 view fields/section and 2 sections/tumor and 3 tumors/group)] to obtain 
the final count ± SEM. 
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Analysis of Serum Inhibition of OV 
 Mice were divided into two groups and treated by daily gavage with ATN-224 (0.7 
mg/mouse dissolved in 100 uL PBS) or PBS (100 uL) (n=6). On day 7 after the initial 
ATN-224 treatment, hrR3 (2x107 pfu) was administered intravenously by a tail vein 
injection. Blood was then drawn from the sub-mandibular vein 20 minutes after hrR3 
injection, blood was spun down for 20 min at 6000 rpm, and virus-containing serum 
supernatant was collected. Mouse serum (5 uL) was incubated with HBSS (45 uL) 
briefly before infecting Vero cells in 48-well plates. Virus titer was determined by viral 
plaque assay41. DMEM media with 2% fetal bovine serum was added 1 hour later, and 
cells were cultured overnight. At 16 hours post infection, cells were treated with 4% 
human IgG, and plaque number was counted 3 days after infection. Plaque numbers 
corresponding to each virus in serum were then converted to virus titer using a standard 
curve obtained for rQnestin34.5 (at multiple known titers) pre-incubated with HBSS. 
In vivo Tumoral Detection of OV 
 U251T3 human gliomas (1.5x107 cells) were implanted subcutaneously into the 
rear flank of nude mice. When tumor volumes reached approximately 250 mm3, tumor-
implanted mice were randomly assigned and treated by daily gavage with ATN-224 (0.7 
mg/mouse dissolved in 100 uL PBS) or PBS (100 uL) for 7 days. 
When analyzing intratumoral administration of OV, rQnestin34.5 (5x105 pfu) was 
injected intratumorally on day 7 and on day 9 after the initial ATN-224 (or PBS) 
treatment, for a total of two injections (n=8). On day 12, three days after the final OV 
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injection, tumors were harvested and processed for virus titration. Briefly, tumors were 
collected and minced into small pieces before incubation for 1 min at 37°C with the 
following enzymes dissolved in HBSS: collagenase Type I (0.05 mg/ml), hyaluronidase 
(0.025 mg/ml), and soybean trypsin inhibitor (0.2 trypsin inhibitor unit/ml, Roche 
Diagnostics, Nutley, NJ). The lysed tumors were centrifuged at 8000 rpm for 20 min, 
and supernatant was stored -80°C.  Virus titers were determined by plaque forming unit 
assay in Vero cells41. In vivo replication results were normalized relative to the total 
tumor weight in each sample (by lysing tumor cells using an adjusted volume of lysis 
buffer) and were calculated as pfu/mL of lysis buffer. 
When evaluating intravenous administration of OV, hrR3 (1x107 pfu) was injected 
intravenously by a tail vein injection on day 7 after the initial ATN-224 (or PBS) 
treatment, one time (n=3). On day 10, subcutaneous tumors were harvested, and total 
DNA was purified using the MasterPure™ Complete DNA & RNA Purification Kit (Cat. 
No. MC85200, Epicentre Biotechnologies), according to the manufacturer’s instructions. 
OV presence was measured by determining the total number of copies of the HSV-
specific ICP4 gene (“OV gene copy”) present in the tumors using absolute quantitative 
real-time PCR (qPCR) analysis. Absolute qPCR was performed using ABI 7500 
Standard Block machine (Applied Biosciences), and each sample was performed in 
triplicate. The following ICP4 primer was used: sense, 5’- 
CGACACGGATCCACGACCC-3’ and antisense, 5’- 
GATCCCCCTCCCGCGCTTCGTCCG-3’. Total OV gene copy was determined by 
generating a linear regression curve using a pK1-2 plasmid containing the ICP4 HSV-1 
viral gene, kindly provided by Dr. Deborah Parris at The Ohio State University. The 
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plasmid was diluted to various concentrations ranging from 100 ng/5 uL to 0.0005 ng/5 
uL DNA. The number of plasmids per ug of DNA was calculated using the total number 
of nucleotides in the plasmid [(amount(ng)*6.022x1023)/(length*1x109*660)]. qPCR was 
performed with the diluted concentrations of the plasmid, and CT value versus gene 
copy number was plotted to give the linear regression standard curve. qPCR samples 
(20 uL per well) were loaded into a 1% agarose gel, and ICP4 gene amplification was 
confirmed by agarose gel electrophoresis post-qPCR. 
Statistical Analysis 
 Student's t-test was used to analyze data for viral replication, glioma cell survival 
in cytotoxicity assay, microvessel density and gene copy changes. Two-tailed P-values 
are displayed. A P-value <0.05 was considered statistically significant in student's t-test. 
All error bars displayed are shown as standard deviations, and all graphs were 
generated with use of Microsoft Excel. To analyze mouse survival data, Kaplan-Meier 
curves were compared using the log rank and Breslow (Generalized Wilcoxon) tests. All 
statistical analyses were performed with the use of SPSS statistical software (version 
14.0; SPSS, Chicago, IL). 
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Chapter 3: Results 
ATN-224 Rescues Copper Inhibition of OV in vitro 
 Copper has been shown to inhibit wild-type HSV-1 through a DNA-damaging 
mechanism induced by copper (II) ions in a reducing environment32. Through its ability 
to chelate copper (II) ions, ATN-224 has the potential to remove copper and its 
inhibitory effects against oncolytic virus (OV) therapy from the tumor microenvironment. 
To test whether ATN-224 can rescue copper inhibition of oncolytic HSV-1 (oHSV), we 
infected gliomas with rQnestin34.5 (for simplicity, referred to as OV) that had just 
previously been incubated with ascorbate buffer (OV alone), buffer and copper 
(OV+copper), or buffer and copper and ATN-224 (OV+copper+ATN224). We quantified 
the results as a measure of total amount of infectious viral particles (for viral replication) 
or as a measure of the percentage of glioma cells that survived treatment (for 
cytotoxicity).  
We first observed that copper, at a physiological concentration of 1 mg/L in 
ascorbate buffer (300 mg/L in HBSS), markedly reduced the ability of rQnestin34.5 
oncolytic virus to replicate in vitro in the human glioma cells U251T3 and Gli36ΔEGFR 
and the patient-derived glioma cells X12V2. When gliomas (4.5x105 cells/plate) were 
treated with virus that had been previously incubated with copper and ATN-224, we 
demonstrated that ATN-224 can restore the ability of rQnestin34.5 to replicate, as 
evidenced by a greater viral load in U251T3 gliomas (total plaque-forming units [pfu] 
following infection, OV+copper vs. OV+copper+ATN224: 1.5625x100 vs. 3.0469×105, 
P=0.001052), in X12V2 gliomas (total pfu following infection, OV+copper vs. 
OV+copper+ATN224: 7.8125x10-1 vs. 2.8125x105, P=0.0001053), and in Gli36ΔEGFR 
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gliomas (total pfu following infection, OV+copper vs. OV+copper+ATN224: 0.00x100 vs. 
3.3875x104, P=0.0005461) (Figure 4A). 
Similarly, copper (1 mg/L) significantly reduced the cytotoxicity of rQnestin34.5 in 
human glioma lines U251T3 and Gli36ΔEGFR and in patient-derived glioma cells 
X12V2. When gliomas (5000 cells/well) were treated with virus that had been previously 
incubated with copper and ATN-224, we demonstrated that ATN-224 can restore the 
ability of rQnestin34.5 to kill gliomas, as evidenced by reduced percentages of U251T3 
gliomas (cell survival following infection, OV+copper vs. OV+copper+ATN224, 
compared to untreated control: 78.0% vs. 25.7%, P<0.0001), X12V2 gliomas (cell 
survival following infection, OV+copper vs. OV+copper+ATN224, compared to untreated 
control: 73.4% vs. 20.9%, P<0.0001), and Gli36ΔEGFR gliomas (cell survival following 
infection, OV+copper vs. OV+copper+ATN224, compared to untreated control: 97.1% 
vs. 18.7%, P<0.0001) that survived treatment (Figure 4B). 
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Figure 4. ATN-224 rescues copper inhibition of OV replication and OV-mediated glioma cell killing 
in vitro. Gliomas (U251T3, X12V2 and Gli36ΔEGFR) were infected with rQnestin34.5 oncolytic virus 
(OV) at multiplicity of infection (MOI) of 0.1. Prior to infection, ATN-224 was incubated with copper, and 
then OV was incubated with ascorbate buffer ± copper (1 mg/L) ± ATN-224 (32 uM). A) Gliomas (4.5x105 
cells/plate) were infected with rQnestin34.5, and cells were harvested for viral isolation 48 hours post 
infection. Viral titers were measured via fluorescence microscopy quantification of green fluorescent 
protein (GFP) expression by rQnestin34.5-infected cells. Total viral load was increased in cells infected 
with OV+copper+ATN224 compared to cells infected with OV+copper, and was comparable to cells 
infected with OV alone. B) Gliomas (5000 cells/well) were infected with rQnestin34.5, and cell survival 
was measured via crystal violet staining 48 hours post infection. Glioma survival was decreased in cells 
infected with OV+copper+ATN224 compared to cells infected with OV+copper, and was comparable to 
cells infected with OV alone (**P<0.001, *P<0.01). 
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In the Absence of Copper, ATN-224 Has No Effect on OV Cytotoxicity in vitro 
 To our knowledge, ATN-224 has never been tested for its effects on modulating 
the efficacy of any oncolytic virus. As a safety checkpoint, we searched for any potential 
antagonistic effects that ATN-224 could have against rQnestin34.5 oncolytic virus. 
Determining if ATN-224 acts by some mechanism to disrupt the efficacy of our original 
OV therapy would indicate whether ATN-224 administration would need to precede OV 
treatment (if found to be antagonistic) or whether ATN-224 could be administered 
concurrently with OV (if found to display no effect) in future in vivo studies. 
 To test this, glioma cells (U251T3, X12V2 and Gli36ΔEGFR, 5000 cells/well) 
were plated in a 96-well plate and were infected with OV (rQnestin34.5) at a multiplicity 
of infection (MOI) of 0.1. Prior to infection, OV was incubated with or without ATN-224 
(32 uM) to assess the effect of ATN-224 on a constant amount of OV. Cytotoxicity was 
assessed as a measure of percentage of cells surviving infection, compared to 
untreated control, and was quantified by crystal violet staining 48 hours post infection. 
Results in all three glioma cell lines show that, in the absence of copper, ATN-224 has 
no significant effect on the ability of rQnestin34.5 to kill glioma cells (Figure 5). 
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Figure 5. In the absence of copper, ATN-224 does not affect OV-mediated cytotoxic killing in vitro. 
Glioma cells (U251T3, X12V2 and Gli36ΔEGFR) were infected with OV (rQnestin34.5), ATN-224, or both 
OV+ATN224. Cell survival was measured via crystal violet staining 48 hours post infection. ATN-224 (32 
uM) showed no significant effect on glioma cell growth following OV infection. 
ATN-224 
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ATN-224 Enhances Anti-Tumor Efficacy of OV Therapy in vivo 
 Having demonstrated the ability of ATN-224 to significantly rescue the inhibitory 
effects of copper on OV replication and cytotoxicity in vitro without by itself adversely 
affecting OV therapy, we were encouraged to test our hypothesis in vivo. This study 
implemented two in vivo models to assess the effect of ATN-224 on the anti-tumor 
efficacy of OV therapy. To do this, we measured tumor size in a subcutaneous 
xenograft glioma model and evaluated mouse survival in an intracranial xenograft 
glioma model. In all of the in vivo experiments in this project, ATN-224 (0.7 mg/mouse 
dissolved in 100 uL PBS) was systemically administered daily via gavage technique, as 
previously described26. 
To study tumor size, U251T3 human gliomas (1.5x107 cells) were implanted 
subcutaneously into athymic nude mice and were treated with PBS, ATN-224, OV, or 
OV+ATN224 (n=10). The oncolytic virus utilized in this study was rQnestin34.5. When 
tumor sizes reached approximately 100 mm3, daily ATN-224 or PBS treatment began. 
On day 13 after the initial ATN-224 treatment, tumors were treated with a single 
intratumoral injection of OV (rQnestin34.5, 5x105 pfu) or PBS. Tumor volumes were 
measured every other day throughout the experiment. Our results indicate that 25 days 
after the initial ATN-224 treatment, tumors treated with a combination of ATN-224 with 
rQnestin34.5 displayed significantly smaller volumes compared to tumors treated with 
rQnestin34.5 alone (21.51 vs. 153.93 mm3, P=0.0383) (Figure 6A). A complete 
response is indicated by the complete regression of a tumor; that is, an impalpable 
tumor. In each of the ATN-224 alone and the OV alone experimental groups, 1 of the 10 
mice made a complete response. However, of the mice treated with a combination of 
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ATN-224 with OV, 7 of the 10 mice exhibited a complete response. After noting the 
tumor-regressing effect of ATN-224 and OV combination therapy in subcutaneous 
tumors, we were interested to see if this anti-tumor effect would also be observed in an 
intracranial tumor model assessing mouse survival. 
 To test this, U87ΔEGFR human gliomas (1x105 cells) were implanted 
intracranially in athymic nude mice and were treated with PBS, ATN-224, OV, or 
OV+ATN224. Intracranial surgery was performed for mice in the PBS and ATN-224 
treatment groups on one day (n=8) and for mice in the OV and OV+ATN224 treatment 
groups on the next day (n=10) in order to distribute the workload of a large surgery. 
Mice from both surgery days were treated under the exact same experimental 
conditions and with the exact same treatment regimens. On day 3 after tumor 
implantation, daily ATN-224 or PBS treatment began. On day 10 after tumor 
implantation (after 7 days of ATN-224 treatment), intracranial tumors were treated with a 
single intratumoral injection of OV (rQnestin34.5, 5x104 pfu) or PBS. Mice were 
monitored closely for signs of morbidity, at which point mice were killed by cervical 
dislocation. Kaplan-Meier analysis revealed a statistically significant increase in mean 
survivals for mice treated with combined ATN-224 and rQnestin34.5 compared to mice 
treated with rQnestin34.5 alone (32.000 vs. 18.600 days, Breslow [generalized 
Wilcoxon] significance test score=0.044) (Figure 6B).
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Figure 6. ATN-224 enhances anti-tumor efficacy of OV therapy in vivo. ATN-224 or PBS was 
systemically administered daily by gavage. A) U251T3 glioma cells (1.5x107 cells) were implanted 
subcutaneously in athymic nude mice, and mice were treated with PBS, ATN-224, OV, or OV+ATN224 
(n=10). OV (rQnestin34.5, 5x105 pfu) was injected intratumorally on day 13 after initial ATN-224 
treatment. Tumor size was measured every other day. Mice treated with combined ATN-224 and OV 
displayed reduced tumor sizes compared to mice treated with OV alone (P=0.0383). B) Kaplan-Meier 
survival curve of mice implanted with intracranial U87ΔEGFR gliomas (1x105 cells) and treated with PBS, 
ATN-224, OV, or OV+ATN224 (n=8). OV (rQnestin34.5, 5x104 pfu) was injected intratumorally 7 days 
after initial ATN-224 treatment. Mouse survival was greater for mice treated with combined ATN-224 and 
OV compared to mice treated with OV alone (Breslow significance test score=0.044). 
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These results suggest that ATN-224 represents a promising co-therapeutic agent 
that can enhance the anti-tumor efficacy of OV therapy in vivo. We next sought to 
identify the physiological mechanisms through which ATN-224 manifests this 
augmentation of OV therapy. 
ATN-224 Decreases Angiogenesis in vivo 
 To begin to answer the question as to how specifically ATN-224 is able to 
enhance the efficacy of OV therapy, we decided to examine the effect of ATN-224 on 
tumor angiogenesis following OV treatment. Kurozumi et al. used an anti-angiogenic 
drug to normalize tumor vasculature, resulting in increased titers of oncolytic virus and 
extended mouse survival20. Therefore, we wanted to test if the improved efficacy of OV 
therapy we observed in vivo could be attributed to the ability of ATN-224 to reduce the 
number of blood vessels present in the tumor microenvironment. 
 Here, U251T3 human gliomas (1.5x107 cells) were implanted subcutaneously 
into athymic nude mice and were treated with PBS, ATN-224, OV, or OV+ATN224 
(n=3). When tumor sizes reached approximately 250 mm3, daily ATN-224  or PBS 
treatment began. On day 7 after initial ATN-224 treatment, tumors were treated with a 
single intratumoral injection of OV (rQnestin34.5, 5x105 pfu) or PBS. On day 10, 
subcutaneous tumors were harvested, sectioned and stained for CD31, which detects 
endothelial cells that line blood vessels20. Blood vessel quantification was determined 
by counting the number of CD31-immunoreactive endothelial cell clusters as individual 
microvessels and calculating an average count per view field. Tumors treated with ATN-
224 had a significantly lower microvessel density than did tumors treated with PBS 
control (ATN-224 vs. PBS: 7.89 vs. 18.72 CD31-positive microvessels/view field, 
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P<0.001; OV+ATN224 vs. OV: 6.72 vs. 16.56 CD31-positive microvessels/view field, 
P<0.001), confirming the anti-angiogenic property of ATN-224 (Figure 7). No significant 
difference was observed in microvessel density between tumors treated with ATN-224 
and OV+ATN224. 
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Figure 7. Reduced vasculature detected in subcutaneous tumors treated with ATN-224. U251T3 gliomas 
(1.5x107 cells) were implanted subcutaneously in athymic nude mice. Mice were treated with ATN-224 or 
PBS via gavage every day (n=3). On day 7 after initial ATN-224 treatment, OV (rQnestin34.5, 5x105 pfu) 
was directly injected into the tumor. On day 10, tumors were harvested. A) Immunohistochemistry, CD31 
stain (red) on subcutaneous tumor sections, 20x magnification. B) Quantification of CD31-
immunoreactive microvessels, 10x magnification. Tumors treated with ATN-224 had lower microvessel 
density than did tumors treated with PBS. 
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ATN-224 Rescues OV from Serum Inhibition in vivo 
 Although host defense mechanisms have been recognized to limit oncolytic virus 
propagation22, 43-44, much fewer studies have examined the effect of angiogenesis—and 
anti-angiogenic drugs, in particular—on OV replication20. We suspected that the anti-
angiogenic property of ATN-224 observed above only partly contributed to the 
enhanced efficacy of OV therapy in vivo. Because ATN-224 chelates copper and, 
theoretically, prevents Cu(II)-mediated DNA damage to our oncolytic HSV, perhaps the 
improved anti-tumor efficacy of OV therapy in vivo was also due to increased levels of 
virus available for glioma destruction following ATN-224 treatment. 
 Our first step in assessing the effect of ATN-224 on OV replication was to 
examine the amount of virus detected in the serum of mice treated with or without ATN-
224. Mice were divided into two groups and treated daily with ATN-224 or PBS (n=6). 
On day 7 after the initial ATN-224 treatment, OV (hrR3, 2x107 pfu) was administered 
intravenously by a tail vein injection. In this experiment, we chose to administer hrR3 
oncolytic virus instead of rQnestin34.5 (as we had previously used in this study) 
because hrR3 had been shown to persist in mouse serum in one study13 and had been 
delivered intravenously in other studies10, 45, whereas rQnestin34.5 had not been tested 
in this manner before (i.e. intravenous administration). Therefore, we believed that hrR3 
would be the more appropriate OV to test using an intravenous administration of virus. 
Blood was drawn from the sub-mandibular vein 20 minutes after OV injection, and virus 
titer was determined by viral plaque assay. Results indicate that mouse serum treated 
with OV+ATN224 permitted the survival of more virus than did mouse serum treated 
with OV alone (1.85x105 vs. 5.25x104 pfu/mL, P=0.004) (Figure 8). 
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Figure 8. Increased viral presence in mouse serum treated with ATN-224. Mice were treated with ATN-
224 or PBS via daily gavage (n=6). On day 7 after initial ATN-224 treatment, OV (hrR3, 2x107 pfu) was 
administered intravenously. Twenty minutes after OV injection, venous blood was collected, and virus titer 
was determined via viral plaque assay. Plaque numbers corresponding to each virus in serum sample 
were converted to virus titer using standard curve obtained for hrR3 virus pre-incubated with HBSS. 
Mouse serum treated with ATN-224 permitted survival of more virus than did mouse serum treated with 
PBS (P=0.004). 
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ATN-224 Increases OV Presence in Tumors in vivo 
 To make a more clinically relevant assessment of the effect of ATN-224 on OV 
propagation in vivo, we next examined the amount of virus detected within the actual 
tumors of mice that had or had not undergone ATN-224 treatment. In both of the 
following experiments, U251T3 human gliomas (1.5x107 cells) were implanted 
subcutaneously into athymic nude mice, and mice were treated daily with either ATN-
224 or PBS when tumor sizes reached approximately 250 mm3. 
 In the first experiment, OV (rQnestin34.5, 5x105 pfu) was injected intratumorally 
on day 7 and on day 9 after the initial ATN-224 (or PBS) treatment, for a total of two 
injections (n=8). On day 12, three days after the final OV injection, tumors were 
harvested and processed for virus titration, quantified by a viral plaque assay. With the 
intratumoral administration of rQnestin34.5, subcutaneous tumors that were treated with 
OV+ATN224 yielded higher viral titers than did tumors treated with OV alone (3.71x104 
vs. 1.12x104 pfu/mL, P=0.018) (Figure 9A). 
 In the second experiment, OV (hrR3, 1x107 pfu) was injected intravenously by a 
tail vein injection on day 7 after the initial ATN-224 (or PBS) treatment, one time (n=5). 
As before, our reasoning for utilizing hrR3 oncolytic virus instead of rQnestin34.5 was 
due to the previously demonstrated intravenous use of hrR3 in other studies10, 45, and 
lack of this literature for rQnestin34.5. On day 10, subcutaneous tumors were 
harvested, and total DNA was purified. OV presence was measured by determining the 
number of copies of the HSV-specific ICP4 gene (“OV gene”) present in the tumors 
using quantitative real-time PCR (qPCR) analysis, confirmed by agarose gel 
electrophoresis post-qPCR (Figure 9B, 9C). Here, with the intravenous administration of 
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hrR3, tumors treated with OV+ATN224 also revealed increased presence of virus 
compared to tumors treated with OV alone (2.81x105 vs. 1.27x105 copies of ICP4 viral 
gene, P=0.0491). 
 These results suggest that the enhanced in vivo efficacy of OV therapy against 
malignant glioma may be attributed to the increased levels of virus present within the 
tumor and the tumor microenvironment as a result of ATN-224 treatment. 
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Figure 9. Increased virus detection in subcutaneous tumors treated with OV+ATN224 compared to 
OV alone in vivo. U251T3 glioma xenografts (1.5x107 cells) were established subcutaneously in nude 
mice. Mice were treated daily with either ATN-224 or PBS, administered systemically by gavage. A) On 
day 7 after initial ATN-224 treatment, OV (rQnestin34.5, 5×105 pfu) was injected intratumorally, and again 
on day 9, for a total of two injections. Three days after the final injection of rQnestin34.5 virus, tumors 
were harvested and processed for virus titration, quantified by viral plaque assay (n=8). B) On day 7 after 
ATN-224 treatment began, OV (hrR3, 1x107 pfu) was injected intravenously. On day 10, tumors were 
harvested and total DNA was purified. ICP4 gene copy (HSV-specific) was quantified by qPCR analysis. 
C) Using DNA from qPCR samples of tumors treated with intravenous OV, confirmation of ICP4 gene via 
agarose gel electrophoresis. Data shows increased viral presence in tumors treated with OV+ATN224 
compared to tumors treated with OV alone. 
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Discussion and Conclusions 
In clinical trials, oncolytic HSV (oHSV) therapy has demonstrated a remarkable 
tolerance, with no evidence of dose-related toxicity in patients. Evidence has shown that 
oHSV replication has been limited to tumor cells and has not been associated with any 
reactivation of latent wild-type HSV-146. However, the results of these studies have 
been inconclusive with respect to the effect of oncolytic virus therapy on patient survival. 
Angiogenesis is critical for invasive tumor growth and plays an important role in tumor 
progression and its response to therapy47. It has been shown that copper plays an 
essential role in angiogenesis, acting as a critical co-factor for several angiogenic 
growth factors33. Additionally, copper can inhibit HSV-1 replication and persistence 
through a DNA-damaging mechanism induced by copper (II) ions in a reducing 
environment32. It has been suggested that copper levels needed for cellular functions 
are much lower than copper levels needed for tumor angiogenesis33. Therefore, a 
logical approach to reducing the detrimental effects of copper on oncolytic HSV-1 
therapy would be to remove copper from the tumor microenvironment. We proposed 
that ATN-224—a second generation analog of tetrathiomolybdate (TM), a copper-
chelating agent that is currently FDA-approved for the treatment of Wilson’s disease—
could inhibit the formation of blood vessels in the tumor microenvironment while 
simultaneously preventing DNA damage to oncolytic HSV-1 by physiologic levels of 
copper. We hypothesized that the combination therapy of ATN-224 with oncolytic virus 
would reduce tumor angiogenesis and enhance the ability of oncolytic virus to destroy 
malignant glioma. 
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In this study, we demonstrated that copper, at a physiologically relevant 
concentration, inhibits OV replication and OV-mediated glioma killing. We showed in 
vitro that, through its chelation of copper, ATN-224 can remove the inhibitory effects of 
copper on OV replication and cytotoxicity, and we showed that ATN-224 by itself has no 
antagonistic effect on the cytotoxic ability of our original OV therapy. Our in vivo results 
indicated that mice treated with the combination of ATN-224 and OV displayed 
significantly reduced tumor sizes and increased mouse survival compared to mice 
treated with OV alone, thus demonstrating that ATN-224 treatment can enhance the 
anti-tumor efficacy of OV therapy in vivo. ATN-224 treatment was shown to reduce 
tumor vasculature following OV infection and to increase the presence of OV in mouse 
serum and in subcutaneous tumors treated both intratumorally and intravenously. 
Overall, these results strongly suggest that the co-treatment of ATN-224 with oncolytic 
virus can significantly improve the poor efficacy profile of conventional clinical oncolytic 
virotherapy. 
The host immune response has been recognized to have an important role in 
limiting viral oncolysis20, 22, 48, and the vascular endothelium is known to be an important 
component of host inflammatory responses49. The key role played by blood vessels in 
increasing tissue inflammation is supported by literature stating that increased 
microvessel density in transgenic mice engineered to overexpress vascular endothelial 
growth factor A (VEGF-A, a stimulator of angiogenesis) led to a significantly increased 
and prolonged inflammatory response compared to wild-type mice. Additionally, this 
amplified inflammatory response could be hindered by antibodies against the VEGF-A 
receptor50. 
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While multiple studies have attempted to exploit anti-angiogenic treatment to 
control the growth of glioblastoma51-53, few have investigated the effect of inhibiting 
angiogenesis in combination with OV therapy. One study in particular employed the 
intracranial, direct intratumoral injection of cRGD peptide (cilengitide, an angiogenesis 
inhibitor) as a pre-treatment to OV therapy20. Because this treatment regimen required 
two intratumoral injections (drug and virus treatment) at separate time points, translation 
of this dose-administration schedule to the clinics for patients with brain tumors would 
not be practical, as a repeat craniotomy would be cost-inefficient and risky for both the 
patient and the health care provider. By using ATN-224, we were able to administer 
anti-angiogenic treatment systemically, thus eliminating the need to directly access the 
tumor at multiple time points. Systemic administration of anti-angiogenic ATN-224 
treatment is much more feasible in its transition to application in a clinical setting. 
As the first generation analog of ATN-224, ammonium tetrathiomolybdate (TM), 
is currently an FDA-approved drug that is used for the treatment of Wilson’s disease, 
the dose-response curve for this drug family is already characterized and understood for 
humans. The anti-angiogenic effects of TM and ATN-224 are being investigated in 
clinical trials as an anti-cancer therapy for multiple tumor modalities, including breast 
cancer, prostate cancer, and lung cancer14. Oncolytic viruses, such as the HSV-1-
derived HSV1716 and G207 viruses, have been studied in clinical trials for their efficacy 
against malignant glioma54. The existing track record of these two treatments in human 
trials greatly encourages the testing of their combination, ATN-224 with oncolytic virus, 
as therapy for brain tumors in humans as well. 
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However, this study has several limitations. The data demonstrating that ATN-
224 rescues the inhibitory effects of copper on OV are only displayed for three brain 
tumor cell types. While the general term is “brain tumor,” each cell line of brain tumors is 
characterized by unique behavior both in its own growth and in its response to 
treatment. Also, our rQnestin34.5 oncolytic virus is designed to be most effective in cell 
types that overexpress the nestin protein gene. To demonstrate breadth of application 
for ATN-224 and rQnestin34.5 combination therapy, we would need to expand our 
testing to include a variety of additional glioma cell lines with varying nestin expression 
levels. Similarly, rQnestin34.5 is an oncolytic virus that is specifically designed for 
therapy against malignant glioma. Collaboration with other cancer labs would be 
required to test the effect of ATN-224 as a co-therapeutic drug with oncolytic viruses 
targeted for other tumor modalities. 
The dosage of ATN-224 used in this experiment was shown in a previous study 
that used TM to reduce copper levels to 20% of baseline26, although the side effects of 
reduced copper levels were not studied in this in vivo investigation of combining anti-
angiogenic treatment with OV therapy. Copper is also known to play a key role in heme 
synthesis, and anemia is the first clinical sign of copper deficiency55. Future in vivo 
studies could incorporate the testing of blood for copper levels as well as hematocrit in 
order to address the potential side effect of anemia induced by copper reduction. 
The results from our in vitro and in vivo studies indicate a potential for increased 
viral replication following ATN-224 treatment in live models. Higher viral titers isolated 
from tumors from mice treated with ATN-224 and OV could potentially lead to toxic 
effects that are associated with an increased viral burden. Since rats and mice are 
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resistant to HSV infection, it would be necessary to evaluate toxicity studies in primate 
models. 
Finally, an essential aspect that must be considered is the blood brain barrier. As 
the anti-angiogenic/oncolytic virus therapeutic strategy of this study targets brain 
cancer, it will be important to note whether ATN-224 crosses the blood brain barrier to 
chelate copper in brain tissue or whether it remains within cerebral vasculature. One 
study suggests the possibility that ATN-224 can indeed cross the blood brain barrier, 
based on evidence from Cu-TM complexes and from studies of copper 
diethyldithiocarbamate, another non-polar lipophilic chelate56-57. This is vital in 
determining whether ATN-224 can prevent the inhibitory effects of copper (II) ions 
against oHSV at the actual site of the virus’s action. 
More immediate future studies of this project will aim to determine the effect of 
ATN-224 on the host immune response. In particular, we would like to examine the 
inflammatory cytokine response, immune cell infiltration and macrophage activity post-
OV treatment in mice treated with or without ATN-224. We would like to assess the 
effect of ATN-224 on OV persistence, analyzing the amount of virus present in tumors 
over several time points. Lastly, we would like to evaluate the biodistribution of OV in 
various organs following intravenous delivery of virus. 
This study aimed to test the effects of ATN-224 on the anti-tumor efficacy of 
oncolytic virus therapy in order to provide a model for the treatment of cancer using anti-
angiogenic agents in combination with oncolytic virus. Additional studies should be 
conducted to evaluate the feasibility of this treatment regimen in combination with 
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existing treatment modalities, so as to implement an effective therapy in patients with 
deadly cancers such as malignant glioma. 
52 
References 
1.  Cancer Facts & Figures 2010. American Cancer Society 2010. 
2.  Kohler BA, Ward E, McCarthy BJ, et al. Annual Report to the Nation on the Status of Cancer, 
1975‐2007, Featuring Tumors of the Brain and Other Nervous System. Journal of the National Cancer 
Institute. 
3.  Penas‐Prado M, Gilbert MR. Molecularly targeted therapies for malignant gliomas: advances and 
challenges. Expert review of anticancer therapy 2007;7:641‐61. 
4.  Tonn JC WM, Rutka JT, Grossman SA. Neuro‐Oncology of CNS Tumors. Germany: Springer; 2006. 
5.  Miller CR, Perry A. Glioblastoma. Arch Pathol Lab Med 2007;131:397‐406. 
6.  Nutt CL, Mani DR, Betensky RA, et al. Gene expression‐based classification of malignant gliomas 
correlates better with survival than histological classification. Cancer research 2003;63:1602‐7. 
7.  Gravendeel LA, Kouwenhoven MC, Gevaert O, et al. Intrinsic gene expression profiles of gliomas 
are a better predictor of survival than histology. Cancer research 2009;69:9065‐72. 
8.  Vitucci M, Hayes DN, Miller CR. Gene expression profiling of gliomas: merging genomic and 
histopathological classification for personalised therapy. Br J Cancer 2011;104:545‐53. 
9.  Kambara H, Okano H, Chiocca EA, Saeki Y. An oncolytic HSV‐1 mutant expressing ICP34.5 under 
control of a nestin promoter increases survival of animals even when symptomatic from a brain tumor. 
Cancer research 2005;65:2832‐9. 
10.  Nomura N, Kasuya H, Watanabe I, et al. Considerations for intravascular administration of 
oncolytic herpes virus for the treatment of multiple liver metastases. Cancer chemotherapy and 
pharmacology 2009;63:321‐30. 
11.  Chung RY, Saeki Y, Chiocca EA. B‐myb promoter retargeting of herpes simplex virus gamma34.5 
gene‐mediated virulence toward tumor and cycling cells. Journal of virology 1999;73:7556‐64. 
12.  Dahlstrand J, Collins VP, Lendahl U. Expression of the class VI intermediate filament nestin in 
human central nervous system tumors. Cancer research 1992;52:5334‐41. 
13.  Wakimoto H, Ikeda K, Abe T, et al. The complement response against an oncolytic virus is 
species‐specific in its activation pathways. Mol Ther 2002;5:275‐82. 
14.  ClinicalTrials.gov. In: U.S. National Institutes of Health; 2011. 
15.  Norton L, Massague J. Is cancer a disease of self‐seeding? Nature medicine 2006;12:875‐8. 
16.  Folkman J. Tumor angiogenesis: therapeutic implications. The New England journal of medicine 
1971;285:1182‐6. 
17.  Aghi M, Cohen KS, Klein RJ, Scadden DT, Chiocca EA. Tumor stromal‐derived factor‐1 recruits 
vascular progenitors to mitotic neovasculature, where microenvironment influences their differentiated 
phenotypes. Cancer research 2006;66:9054‐64. 
18.  Abe T, Terada K, Wakimoto H, et al. PTEN decreases in vivo vascularization of experimental 
gliomas in spite of proangiogenic stimuli. Cancer research 2003;63:2300‐5. 
19.  Brat DJ, Kaur B, Van Meir EG. Genetic modulation of hypoxia induced gene expression and 
angiogenesis: relevance to brain tumors. Front Biosci 2003;8:d100‐16. 
20.  Kurozumi K, Hardcastle J, Thakur R, et al. Effect of tumor microenvironment modulation on the 
efficacy of oncolytic virus therapy. Journal of the National Cancer Institute 2007;99:1768‐81. 
21.  Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. 
Science (New York, NY 2005;307:58‐62. 
22.  Fulci G, Breymann L, Gianni D, et al. Cyclophosphamide enhances glioma virotherapy by 
inhibiting innate immune responses. Proceedings of the National Academy of Sciences of the United 
States of America 2006;103:12873‐8. 
23.  Dierick HA, Ambrosini L, Spencer J, Glover TW, Mercer JF. Molecular structure of the Menkes 
disease gene (ATP7A). Genomics 1995;28:462‐9. 
53 
24.  Pfeiffer RF. Wilson's Disease. Semin Neurol 2007;27:123‐32. 
25.  Hu GF. Copper stimulates proliferation of human endothelial cells under culture. Journal of 
cellular biochemistry 1998;69:326‐35. 
26.  Pan Q, Kleer CG, van Golen KL, et al. Copper deficiency induced by tetrathiomolybdate 
suppresses tumor growth and angiogenesis. Cancer research 2002;62:4854‐9. 
27.  Soncin F, Guitton JD, Cartwright T, Badet J. Interaction of human angiogenin with copper 
modulates angiogenin binding to endothelial cells. Biochemical and biophysical research 
communications 1997;236:604‐10. 
28.  Tisato F, Marzano C, Porchia M, Pellei M, Santini C. Copper in diseases and treatments, and 
copper‐based anticancer strategies. Medicinal research reviews;30:708‐49. 
29.  Percival S. Copper and immunity. Am J Clin Ntr 1998;67:1064‐8. 
30.  Mandinova A, Soldi R, Graziani I, et al. S100A13 mediates the copper‐dependent stress‐induced 
release of IL‐1alpha from both human U937 and murine NIH 3T3 cells. Journal of cell science 
2003;116:2687‐96. 
31.  Zoli A, Altomonte L, Caricchio R, et al. Serum zinc and copper in active rheumatoid arthritis: 
correlation with interleukin 1 beta and tumour necrosis factor alpha. Clinical rheumatology 
1998;17:378‐82. 
32.  Sagripanti JL, Routson LB, Bonifacino AC, Lytle CD. Mechanism of copper‐mediated inactivation 
of herpes simplex virus. Antimicrobial agents and chemotherapy 1997;41:812‐7. 
33.  Goodman VL, Brewer GJ, Merajver SD. Control of copper status for cancer therapy. Current 
cancer drug targets 2005;5:543‐9. 
34.  Hou G, Abrams GD, Dick R, Brewer GJ. Efficacy of tetrathiomolybdate in a mouse model of 
multiple sclerosis. Transl Res 2008;152:239‐44. 
35.  Pan Q, Bao LW, Merajver SD. Tetrathiomolybdate inhibits angiogenesis and metastasis through 
suppression of the NFkappaB signaling cascade. Mol Cancer Res 2003;1:701‐6. 
36.  Pan Q, Bao LW, Kleer CG, Brewer GJ, Merajver SD. Antiangiogenic tetrathiomolybdate enhances 
the efficacy of doxorubicin against breast carcinoma. Mol Cancer Ther 2003;2:617‐22. 
37.  Lowndes SA, Adams A, Timms A, et al. Phase I study of copper‐binding agent ATN‐224 in patients 
with advanced solid tumors. Clin Cancer Res 2008;14:7526‐34. 
38.  Lowndes SA, Harris AL. The role of copper in tumour angiogenesis. J Mammary Gland Biol 
Neoplasia 2005;10:299‐310. 
39.  Donate F, Juarez JC, Burnett ME, et al. Identification of biomarkers for the antiangiogenic and 
antitumour activity of the superoxide dismutase 1 (SOD1) inhibitor tetrathiomolybdate (ATN‐224). Br J 
Cancer 2008;98:776‐83. 
40.  Wakimoto H, Fulci G, Tyminski E, Chiocca EA. Altered expression of antiviral cytokine mRNAs 
associated with cyclophosphamide's enhancement of viral oncolysis. Gene therapy 2004;11:214‐23. 
41.  Sundaresan P, Hunter WD, Martuza RL, Rabkin SD. Attenuated, replication‐competent herpes 
simplex virus type 1 mutant G207: safety evaluation in mice. Journal of virology 2000;74:3832‐41. 
42.  Choi WW, Lewis MM, Lawson D, et al. Angiogenic and lymphangiogenic microvessel density in 
breast carcinoma: correlation with clinicopathologic parameters and VEGF‐family gene expression. Mod 
Pathol 2005;18:143‐52. 
43.  Lamfers ML, Fulci G, Gianni D, et al. Cyclophosphamide increases transgene expression 
mediated by an oncolytic adenovirus in glioma‐bearing mice monitored by bioluminescence imaging. 
Mol Ther 2006;14:779‐88. 
44.  Thomas MA, Spencer JF, Toth K, Sagartz JE, Phillips NJ, Wold WS. Immunosuppression enhances 
oncolytic adenovirus replication and antitumor efficacy in the Syrian hamster model. Mol Ther 
2008;16:1665‐73. 
54 
45.  Kulu Y, Dorfman JD, Kuruppu D, et al. Comparison of intravenous versus intraperitoneal 
administration of oncolytic herpes simplex virus 1 for peritoneal carcinomatosis in mice. Cancer Gene 
Ther 2009;16:291‐7. 
46.  Cutter JL, Kurozumi K, Chiocca EA, Kaur B. Gene therapeutics: the future of brain tumor therapy? 
Expert review of anticancer therapy 2006;6:1053‐64. 
47.  Folkman J. Role of angiogenesis in tumor growth and metastasis. Semin Oncol 2002;29:15‐8. 
48.  Wong HH, Lemoine NR, Wang Y. Oncolytic Viruses for Cancer Therapy: Overcoming the 
Obstacles. Viruses 2010;2:78‐106. 
49.  Frantz S, Vincent KA, Feron O, Kelly RA. Innate immunity and angiogenesis. Circ Res 2005;96:15‐
26. 
50.  Kunstfeld R, Hirakawa S, Hong YK, et al. Induction of cutaneous delayed‐type hypersensitivity 
reactions in VEGF‐A transgenic mice results in chronic skin inflammation associated with persistent 
lymphatic hyperplasia. Blood 2004;104:1048‐57. 
51.  Friedman HS, Prados MD, Wen PY, et al. Bevacizumab alone and in combination with irinotecan 
in recurrent glioblastoma. J Clin Oncol 2009;27:4733‐40. 
52.  Kreisl TN, Kim L, Moore K, et al. Phase II trial of single‐agent bevacizumab followed by 
bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol 2009;27:740‐5. 
53.  Vredenburgh JJ, Desjardins A, Herndon JE, 2nd, et al. Bevacizumab plus irinotecan in recurrent 
glioblastoma multiforme. J Clin Oncol 2007;25:4722‐9. 
54.  Aghi M, Martuza RL. Oncolytic viral therapies ‐ the clinical experience. Oncogene 2005;24:7802‐
16. 
55.  Brewer GJ, Dick RD, Grover DK, et al. Treatment of metastatic cancer with tetrathiomolybdate, 
an anticopper, antiangiogenic agent: Phase I study. Clin Cancer Res 2000;6:1‐10. 
56.  Haywood S, Dincer Z, Holding J, Parry NM. Metal (molybdenum, copper) accumulation and 
retention in brain, pituitary and other organs of ammonium tetrathiomolybdate‐treated sheep. Br J Nutr 
1998;79:329‐31. 
57.  Allain P, Krari N. Diethyldithiocarbamate, copper and neurological disorders. Life Sci 
1991;48:291‐9. 
 
 
